SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1144FDA approves Victrelis (boceprevir) with broad label: siliconinvestor.com ObviDewDiligence_on_SI-5/13/2011
1143Unfortunately stupidity is good for the HCV players. By Michael Smith, North Arkrw-5/7/2011
1142Seeking Alpha <i>Vertex Pharmaceuticals (VRTX): Q1 EPS of -$0.91 beats bytom pope-5/4/2011
1141While I somewhat agree with you, do gap ups on huge volume usually signal the enJamesK-4/27/2011
1140Agreed, was a great trade. Onward. ditchDitchdigger14/26/2011
1139It’s a good time to take some chips off the table, IMO: siliconinvestor.comDewDiligence_on_SI-4/26/2011
1138More buyers than sellers. ;-) Waited a long time, my world, for only about 60%scaram(o)uche-4/26/2011
1137I'm a little baffled by the big move. The Doc's were positive with questJamesK-4/26/2011
1136sweeeeeeeeeeeeeeeeeeeeeeeeet!scaram(o)uche-4/26/2011
1135Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery atnsaf-4/15/2011
1134Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantlytnsaf-4/1/2011
1133Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic tnsaf-3/29/2011
1132Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy wtnsaf-3/10/2011
1131News from Pharmasset that impacts Vertex: Message 27222722tnsaf-3/9/2011
1130New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For tnsaf-3/8/2011
1129Vertex Pharmaceuticals Inc. Presentation at the Cowen and Company Health Care Cotnsaf-3/6/2011
1128Wider genotype coverage than Telaprevir ought to ensure a market for a drug suchDewDiligence_on_SI-3/2/2011
1127<i>second-generation competition to Telaprevir</i> Presumably any sBiomaven-3/2/2011
1126TMC435 phase-2b results look good: siliconinvestor.com This is shaping up to DewDiligence_on_SI-2/23/2011
1125Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Functscaram(o)uche-2/23/2011
1124U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatmetnsaf-1/20/2011
1123gotcha, my hope is investors are starved for some positive news,enough to move tDitchdigger-1/1/2011
1122What’s I’m saying is that the FDA’s granting a priority review probably won’t beDewDiligence_on_SI-1/1/2011
1121yes, but news on that fait accompli should be out within 45 days of the applicatDitchdigger-1/1/2011
1120Priority review is a fait accompli, IMO.DewDiligence_on_SI-1/1/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News